Aug 2026
PDE5 Inhibitor LW1646 Improves Kidney Fibrosis by Alleviating ER Stress and Maintaining Mitochondrial Homeostasis.
Renal fibrosis is the terminal pathological manifestation of most chronic kidney diseases. The phosphodiesterase type 5 (PDE5) inhibitors have shown therapeutic potentials in a wide array of chronic conditions. LW1646 is a newly identified inhibitor with high specificity and potency against PDE5. The current study aims...
Minghui Wang, Meng Li, Xi Yuan et al.
· Free Radical Biology & Medic... · 0 citations